MedTrace Logo

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

NCT02189343 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2019-11-21

No results posted yet for this study

Summary

To determine the maximum tolerated dose (MTD), if present, and dose schedule of ACY-1215 (ricolinostat) in combination with pomalidomide and low-dose dexamethasone in patients with relapsed-and-refractory multiple myeloma.

Conditions

Interventions

DRUG

ACY-1215 in combination with pomalidomide and dexamethasone

Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Sumit Madan, MD · The University of Texas Health Science Center at San Antonio

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-15
Primary Completion
2018-04-18
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02189343 on ClinicalTrials.gov